aTyr Pharma, Inc.(US:ATYR)2025-11-06 21:08Financial Performance - aTyr Pharma reported a consolidated net loss of $25.7 million for Q3 2025, compared to a net loss of $17.3 million in Q3 2024, reflecting an increase of 48% year-over-year[14] - Total revenues for Q3 2025 were $190,000, compared to $235,000 in Q3 2024, indicating a decrease of 19%[14] - General and administrative expenses for Q3 2025 were $4.8 million, compared to $3.3 million in Q3 2024, reflecting a 44% increase[14] - The total operating expenses for Q3 2025 were $26.9 million, up from $18.1 million in Q3 2024, marking a 48% increase[14] Research and Development - Research and development expenses for Q3 2025 were $22.1 million, up from $14.8 million in Q3 2024, representing a 49% increase[14] - The Phase 3 EFZO-FIT™ study did not meet its primary endpoint but showed clinical benefits for the 5.0 mg/kg efzofitimod group across multiple efficacy measures[7] - Enrollment in the Phase 2 EFZO-CONNECT™ study is expected to be completed in the first half of 2026, with promising interim data reported earlier[2] - The company presented results from the Phase 3 EFZO-FIT™ study at the European Respiratory Society Congress 2025, highlighting its significance in the field[7] Future Plans - aTyr Pharma plans to meet with the FDA in Q1 2026 to discuss the path forward for efzofitimod in pulmonary sarcoidosis[4] Cash Position - The company ended Q3 2025 with $92.9 million in cash, cash equivalents, restricted cash, and investments, an increase from $75.1 million at the end of 2024[16]